

NOXXON PHARMA AG ANNOUNCES RESEARCH & DEVELOPMENT ALLIANCE WITH ROCHE REGARDING INFLAMMATORY DISEASES.

Berlin, Germany, November 9, 2007 -- NOXXON Pharma AG (NOXXON) announced today that it has entered into a research and development collaboration with Roche regarding the discovery and development of Spiegelmers® for the treatment of inflammatory diseases. In the partnership NOXXON will use its Spiegelmer technology to identify inhibitors against two contractually named protein targets. Roche will conduct all pre-clinical and clinical development as well as the worldwide commercialization of products. Under the terms of the agreement NOXXON will receive an upfront fee and research compensation, as well as additional payments for the achievement of specified development events. In addition NOXXON is eligible to collect royalties on the sale of commercialized products.

“This partnership is another endorsement of the Spiegelmer technology and an indicator of the growing enthusiasm in the potential of Spiegelmers for treating disease,” commented Sven Klussmann, NOXXON’s CEO and CSO. “Roche’s R & D achievements and its partnering record in the last decades speak for themselves,” Klussmann added. “We are excited to work with a company that not only possesses tremendous expertise in the area of inflammatory diseases, but understands the process of building successful long-term relationships with young innovative biotech enterprises such as our own.”

Spiegelmers® are synthetic mirror-image RNA molecules not found in nature. Thanks to their unique mirror image configuration Spiegelmers® are not subject to degradation by nucleases. By screening oligonucleotide libraries of unrivalled size containing over 10^{15} different compounds, NOXXON identifies Spiegelmers® that bind and inhibit their target molecules with high specificity and affinity.

About NOXXON Pharma AG:

Based on one of the biggest and best protected patent portfolios in the industry, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info:

<http://www.noxxon.net>

General contact:

Emmanuelle Camerer

NOXXON Pharma AG

Max-Dohrn-Strasse 8-10

10589 Berlin, Germany

Phone: + 49 30 72 62 47 0

FAX: + 49 30 72 62 47 225

Email: ecamerer@noxxon.net